dsRNA QPI-1007 for Retinal Ganglion Cell Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective therapies for optic neuropathies, particularly for non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma, which result in the death of retinal ganglion cells, with current treatments only managing symptoms and not addressing the long-term course of the disease.
Innovation Solution
Administration of a therapeutically effective dose of a double-stranded RNA compound, QPI-1007, that down-regulates Caspase 2 expression in the eye, either as a single treatment or through a regimen with varying dosing intervals, to provide neuroprotection and prevent further vision loss in patients with ocular diseases or injuries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (lowering intraocular pressure, corticosteroids, tumor removal) are used for optic neuropathies, then symptomatic management is achieved, but long-term disease course is not affected and retinal ganglion cell death continues
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (Caspase-2) responsible for retinal ganglion cell apoptosis in optic neuropathies. By using double-stranded RNA molecules that specifically bind to Caspase-2 mRNA, the invention isolates and interferes with the harmful apoptotic pathway without affecting other physiological processes, thereby preventing cell death while maintaining overall ocular function.
Solution Approach 2:
The double-stranded RNA molecules serve as intermediary agents between the administered therapy and the Caspase-2 protein. These RNA molecules bind to Caspase-2 mRNA and prevent its translation into protein, acting as a molecular mediator that blocks the apoptotic pathway without directly interacting with the cell death machinery itself. This intermediary approach allows for selective inhibition of the harmful pathway.
2Object-generated harmful factors
If double-stranded RNA compounds are administered to down-regulate Caspase 2 expression, then neuroprotection and prevention of vision loss are achieved, but treatment complexity and dosing regimen requirements increase
Solution Approach 1:
The patent employs periodic administration of double-stranded RNA compounds at specific dosing intervals (e.g., every 2-4 weeks) to maintain therapeutic levels of Caspase-2 inhibition. This periodic dosing strategy ensures continuous neuroprotection while allowing for pharmacokinetic recovery periods, balancing efficacy with treatment feasibility. The regular intervals maintain sufficient drug concentration to prevent vision loss without requiring continuous complex monitoring.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment effectively reduces the death of retinal ganglion cells and provides neuroprotection, slowing the progression of optic neuropathies such as NAION and glaucoma, as evidenced by improved visual acuity and visual field preservation in clinical studies.
Implementation Method 1
double-stranded RNA molecules targeting, inter alia, Caspase 2
Data Source
AI summary
The present disclosure relates to methods of treating a patient suffering from or at risk of developing an ocular disease, disorder or injury, and includes treatment regimens using a double-stranded RNA compound that down-regulates CASP2 expression, or a pharmaceutically acceptable salt thereof.